LT3397273T - Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui - Google Patents

Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui

Info

Publication number
LT3397273T
LT3397273T LTEP16826898.5T LT16826898T LT3397273T LT 3397273 T LT3397273 T LT 3397273T LT 16826898 T LT16826898 T LT 16826898T LT 3397273 T LT3397273 T LT 3397273T
Authority
LT
Lithuania
Prior art keywords
glucosidase
treatment
acid alpha
pompe disease
augmented
Prior art date
Application number
LTEP16826898.5T
Other languages
English (en)
Inventor
Hung V. Do
Richie Khanna
Russell GOTSCHALL
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Priority claimed from PCT/US2016/069243 external-priority patent/WO2017117407A1/en
Publication of LT3397273T publication Critical patent/LT3397273T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
LTEP16826898.5T 2015-12-30 2016-12-29 Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui LT3397273T (lt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08
PCT/US2016/069243 WO2017117407A1 (en) 2015-12-30 2016-12-29 Augmented acid alpha-glucosidase for the treatment of pompe disease

Publications (1)

Publication Number Publication Date
LT3397273T true LT3397273T (lt) 2021-06-25

Family

ID=60186557

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP16826898.5T LT3397273T (lt) 2015-12-30 2016-12-29 Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui
LTEP21174249.9T LT3957320T (lt) 2015-12-30 2016-12-29 Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP21174249.9T LT3957320T (lt) 2015-12-30 2016-12-29 Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui

Country Status (15)

Country Link
EP (3) EP3397273B1 (lt)
CN (1) CN108472340A (lt)
CY (1) CY1124637T1 (lt)
DK (2) DK3957320T3 (lt)
ES (2) ES2965190T3 (lt)
FI (1) FI3957320T3 (lt)
HK (1) HK1253014A1 (lt)
HR (2) HRP20231465T1 (lt)
HU (2) HUE064049T2 (lt)
LT (2) LT3397273T (lt)
PL (2) PL3397273T3 (lt)
PT (2) PT3397273T (lt)
RS (2) RS64843B1 (lt)
SI (2) SI3397273T1 (lt)
TW (2) TW202245831A (lt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ES2686775T3 (es) 2003-01-31 2018-10-19 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
EP3441090A1 (en) 2005-05-17 2019-02-13 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
HUE051377T2 (hu) 2008-02-12 2021-03-01 Amicus Therapeutics Inc Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére
US20110070643A1 (en) * 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
EP3871688B1 (en) 2012-05-03 2024-03-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
US9694056B2 (en) 2012-07-17 2017-07-04 Amicus Therapeutics, Inc. α-galactosidase A and 1-deoxygalactonojirimycin co-formulation
BR112017005810A2 (pt) * 2014-09-30 2018-02-27 Amicus Therapeutics Inc alfa-glucosidase ácida altamente potente com carboidratos melhorados

Also Published As

Publication number Publication date
DK3397273T3 (da) 2021-08-09
RS64843B1 (sr) 2023-12-29
LT3957320T (lt) 2023-12-11
SI3397273T1 (sl) 2021-11-30
SI3957320T1 (sl) 2024-01-31
CY1124637T1 (el) 2022-07-22
EP3397273A1 (en) 2018-11-07
EP3957320A1 (en) 2022-02-23
EP4285902A2 (en) 2023-12-06
HUE054733T2 (hu) 2021-09-28
HK1253014A1 (zh) 2019-06-06
TW201726163A (zh) 2017-08-01
ES2965190T3 (es) 2024-04-11
CN108472340A (zh) 2018-08-31
PL3957320T3 (pl) 2024-02-19
EP4285902A3 (en) 2024-02-21
FI3957320T3 (fi) 2023-11-23
PT3957320T (pt) 2023-11-23
RS62212B1 (sr) 2021-09-30
TW202245831A (zh) 2022-12-01
EP3957320B1 (en) 2023-08-23
TWI753874B (zh) 2022-02-01
HRP20231465T1 (hr) 2024-03-01
DK3957320T3 (da) 2023-11-27
EP3397273B1 (en) 2021-05-19
HRP20210894T1 (hr) 2021-07-23
PL3397273T3 (pl) 2021-12-06
PT3397273T (pt) 2021-08-09
HUE064049T2 (hu) 2024-02-28
ES2883844T3 (es) 2021-12-09

Similar Documents

Publication Publication Date Title
IL283837A (en) Improved acid alpha-glucosidase for the treatment of Pompe disease
HK1259458A1 (zh) 用於治療心血管疾病的吉卡賓組合
IL253945B (en) kdm1a inhibitors to treat the disease
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
IL270530A (en) Recombinant human acid alpha-glucosidase
IL255506A (en) A method for treating a neurological disease
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
EP3310377A4 (en) Method of treating crohn's disease
GB201515244D0 (en) Treatment of inflammatory disease or condition
EP3362085C0 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH MUCIN
HK1253014A1 (zh) 用於治療龐貝氏病的增强的酸性α-葡糖苷酶
HK1245146A1 (zh) 尿酸性或痛風性疾病的預防或治療
GB201504413D0 (en) Treatment of disease
AU2015902286A0 (en) Method Of Treating Crohn's Disease
AU2015902358A0 (en) Treatment of inflammatory disease